Delving into the Latest Updates on Risankizumab-RZAA with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Risankizumab, Risankizumab (Genetical Recombination), RZB

+ [9]

Target

IL-23p19

Action

inhibitors

Mechanism

IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [3]

Active Indication

Crohn's disease, active moderateCrohn's disease, active severeColitis, Ulcerative+ [12]

Inactive Indication

Ankylosing SpondylitisDermatitis, AtopicGeneralized Pustular Psoriasis+ [6]

Originator Organization

AbbVie, Inc.

Active Organization

AbbVie, Inc.Boehringer Ingelheim Pharma GmbH & Co., KGAbbVie Deutschland GmbH & Co. KG

+ [3]

Inactive Organization

Boehringer Ingelheim GmbH

License Organization

Boehringer Ingelheim GmbH

AbbVie, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (26 Mar 2019),

Arthritis, PsoriaticErythrodermic psoriasisPsoriasis vulgaris+ [2]

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Sequence Code 181110L

Source: *****

Sequence Code 181112H

Source: *****

This study, titled "IL-23 Inhibitor Ustekinumab for the Treatment of Fibrotic Crohn's Disease: A Prospective, Open-Label, Randomized Controlled Study," is conducted by researchers from the First Affiliated Hospital of Wenzhou Medical University. The primary aim of this research is to evaluate the efficacy and safety of ustekinumab, an IL-23 inhibitor, for patients with fibrostenotic Crohn's disease (CD) who have failed standard treatments.
The study is a prospective, open-label, randomized controlled trial involving 260 participants across three major hospitals: the First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province, and the Second Affiliated Hospital of Wenzhou Medical University. The participants are divided into two groups: one receiving ustekinumab and the other receiving a placebo. The study is designed to assess whether ustekinumab can improve clinical outcomes and reduce fibrosis progression in patients with fibrotic CD.
The study involves a comprehensive assessment of participants, including clinical history, physical examination, laboratory tests, and imaging studies. Key inclusion criteria include age between 18-80 years, confirmed diagnosis of fibrostenic CD, and failure of conventional or biological therapies. Participants are excluded if they are under 18, pregnant, breastfeeding, or have certain medical conditions that could interfere with the study.
The primary endpoint of the study is a clinical-imaging composite endpoint, which includes imaging assessment of bowel wall thickness and clinical symptoms. Secondary endpoints include safety, tolerability, and various functional and quality of life indicators. The study also explores the potential of ustekinumab to modulate immune responses and fibrosis-related biomarkers.
The study is expected to run from October 2025 to October 2028, with follow-up visits scheduled at regular intervals. The results will provide valuable insights into the potential of ustekinumab as a novel treatment for fibrotic CD, offering a new therapeutic option for patients who do not respond to existing treatments.
This research is crucial because fibrotic CD is a severe and progressive disease with limited treatment options. Ustekinumab, by targeting the IL-23 pathway, may offer a more effective and targeted approach to manage this condition. The study's findings could significantly impact clinical practice and improve patient outcomes.
For more detailed information, please refer to the study protocol document titled "IL-23 Inhibitor Ustekinumab for the Treatment of Fibrotic Crohn's Disease: A Prospective, Open-Label, Randomized Controlled Study" dated September 2, 2025. For further inquiries, contact the principal investigators Dr. Wu Fang or Dr. Wu Xiaoli at the First Affiliated Hospital of Wenzhou Medical University.

Start Date20 Oct 2025

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

[+2]

NCT07138898

/ Not yet recruitingPhase 2IIT

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

Start Date01 Sep 2025

Sponsor / Collaborator

NYU Langone Health

NCT07071519

/ RecruitingPhase 3

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants with moderate to severely active UC. Adverse events and change in disease activity will be assessed.
Risankizumab is an approved medication for moderate to severe UC in multiple countries and is being developed for the treatment of UC in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based maintenance regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Around 120 pediatric participants with UC will be enrolled at around 80 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Start Date28 Jul 2025

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Risankizumab-RZAA

Login to view more data

100 Translational Medicine associated with Risankizumab-RZAA

Login to view more data

100 Patents (Medical) associated with Risankizumab-RZAA

Login to view more data

680

Literatures (Medical) associated with Risankizumab-RZAA

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis

Review

Author: Sun, YuanQiang ; Zhao, XiTong ; Li, WenChao ; Liu, Hong ; Zhang, LiHong

BACKGROUND:

Multiple biologics are available for psoriasis treatment, but switching treatments is often necessary at some point. The choice between intraclass or interclass biologic switching has not been extensively investigated.

METHODS:

Two independent authors searched the databases PubMed and EMBASE for studies reporting on biologic switching in psoriasis patients. Our study was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.

RESULTS:

A total of 19 publications, comprising 679 patients, were included. The intraclass switching group consisted of 519 patients, while the interclass switching group included 139 patients. For intraclass switching, there are respectively 160, 326 and 33 patients switched of TNF-α, IL-17, IL-23. For interclass switching, 11 patients switched from TNF-α to IL-17, 6 from IL-17 to IL-23, 41 from IL-17 to IL-12/23, 29 from IL-17 to TNF-α, 15 from IL-12/23 to IL-17, 8 from IL-12/23 to IL-23. After 12 weeks, the proportion of patients achieving Psoriasis Area and Severity Index (PASI)75 was significantly higher in the intraclass switching group compared to the interclass switching group. However, after 16-52 weeks, the PASI75 proportions were comparable between the groups.

CONCLUSION:

Intraclass switching shows better short-term efficacy than interclass switching. However, in the long term, both switching strategies are effective and safe. This study also shows that adalimumab, ixekizumab, and risankizumab are the preferred agents for intraclass switching, whereas guselkumab serves as the primary agent for interclass transitions.

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe

Review

Author: Ständer, S. ; Thaçi, D.

Background: Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.Objective: While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.Methods: This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.Results: Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.Conclusion: Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.

01 Dec 2025·Current gastroenterology reports

New Kids on the Block: IL-23 Inhibitors in IBD Management

Review

Author: Sandhu, Jeevin ; Patel, Anish ; Dulaney, David ; Jones, Kara ; Jones, Jacob

PURPOSE OF THE REVIEW:

Review the efficacy and safety of IL2319 inhibitors in the management of IBD.

RECENT FINDINGS:

Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.

391

News (Medical) associated with Risankizumab-RZAA

31 Oct 2025

·www.fiercepharma.com

AbbVie boosts revenue forecast by $400M thanks to booming sales of Skyrizi, Rinvoq

AbbVie has boosted its 2025 revenue projection to a company record $60.9 billion. It is the third straight quarter that the Illinois drugmaker has adjusted the sales figure positively. For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion.The estimate is $1.9 billion higher than AbbVie's projection from the start of the year, another indication that the company continues to be surprised by the performance of immunology stalwarts Skyrizi and Rinvoq and that it has rebounded from the 2023 loss of patent protection in the United States for Humira, the first drug ever to generate more than $20 billion in annual sales.“Clearly, the momentum is there,” AbbVie CEO Rob Michael said on a Friday conference call. “We’ve beaten and raised in every quarter in 2025.”The new forecast reflects expectations that Skyrizi sales will reach $17.3 billion in 2025, which is a $200 million increase from AbbVie's previous estimate based on the drug's market share gains in psoriasis and inflammatory bowel disease (IBD), chief financial officer Scott Reents said.In the third quarter, Skyrizi sales reached $4.7 billion, up 47% year-over-year, while Rinvoq pulled in $2.2 billion for a 35% boost. The $6.9 billion the duo generated in Q3 far exceeds the most ever racked up by Humira in a single quarter, which was $5.6 billion in Q4 of 2022 before its exclusivity lapsed.As challengers come at Skyrizi with advancements—such as Johnson & Johnson’s FDA expansion last month for Tremfya in ulcerative colitis—there remains much room for growth because of the rapid expansion in the use of drugs in the class, AbbVie’s chief commercial officer Jeff Stewart explained.“We know that Tremfya is going to gain some market share,” Stewart said. “But what’s actually happening is that the category or the class of IL-23s is expanding incredibly rapidly and we view this as a positive. We said before, this is not a zero-sum game.”Stewart added that a year ago, the market share of IL-23 penetration in ulcerative colitis was 5%. It’s now close to 40%.“This is a dramatic change in the adoption of the IL-23s,” Stewart added. “It’s just not a Skyrizi story. AbbVie has uniquely a one-two punch in this market. We got Skyrizi and Rinvoq.”Investors have been taking note of AbbVie's momentum. According to GlobalData on Friday, AbbVie posted a 25% increase in its market cap in the third quarter, which exceeded that of any other company among the top 15 in the biopharma industry. The company’s market cap did take a hit earlier this month, however, when it revealed a $2.7 billion hit tied to acquired in-process research and development (IPR&D) expenses and milestones.Still, the company's third-quarter results evidently left something to be desired, as shares slipped by about 4% by midday. Overall, in the third quarter, AbbVie’s revenues came in at $15.78 billion, a 9% year-over-year increase, topping consensus by $200 million.Michael also pointed to strong sales in the company’s neuroscience portfolio. While dropping its annual sales estimate on cosmetic Botox by $200 million, AbbVie also increased its sales projection of its neuroscience products by $200 million, spread across gains for antipsychotic treatment Vraylar, new Parkinson’s disease drug Vyalev, and Botox’s therapeutic indications. Humira sales fell to $993 million, a 55% decline, marking the first time since 2007 that its quarterly sales failed to reach $1 billion.

Financial StatementDrug ApprovalBiosimilar

31 Oct 2025

·firstwordpharma.com

Skyrizi, Rinvoq continue to fuel AbbVie's immunology surge in Q3

Soaring demand for AbbVie's immunology heavyweights Skyrizi and Rinvoq powered its third-quarter results ahead of forecasts. Together, the two therapies generated roughly half the drugmaker's total quarterly revenue of $15.8 billion, which was up 9.1% year-on-year, company officials said Friday.Skyrizi brought in $4.7 billion during the quarter, a nearly 47% jump from the same time last year, edging past forecasts of roughly $4.5 billion. Rinvoq posted $2.2 billion in sales, up a little over 35% year-over-year and slightly above projections.AbbVie's immunology division overall brought in $7.9 billion, up almost 12%, helping offset the ongoing decline of Humira, which saw sales cut in half to $993 million amid intensifying biosimilar competition. AbbVie has said it expects Skyrizi and Rinvoq to bring in a combined $31 billion in sales by 2027, including $20 billion from Skyrizi and $11 billion from Rinvoq."Investors will continue to monitor the competitive landscape for key indications, such as (inflammatory) bowel disease, but we continue to see Skyrizi and Rinvoq driving strong near-term growth for the company," remarked William Blair analyst Matt Phipps.The neuroscience division posted another strong quarter, with sales climbing about 20% to $2.8 billion. Antipsychotic medicine Vraylar rose 6.7% to $934 million, while migraine treatments Ubrelvy and Qulipta saw sales growing 31.5% and 64.1% to $354 million and $288 million, respectively. Chief Commercial Officer Jeff Stewart also highlighted the "very impressive" launch trajectory of its new Parkinson's disease therapy Vyalev, approved a little over a year ago, which generated $138 million in third-quarter revenue – up 40% on a sequential basis.The oncology portfolio held steady in the third quarter, generating $1.7 billion in revenue, roughly flat year-over-year as gains in newer products offset weakness in older ones. Imbruvica sales were down nearly 15% to $706 million amid rising competition. Elahere, the company's antibody-drug conjugate (ADC) for ovarian cancer, climbed a little over 23% to $170 million, while newer lymphoma drug Epkinly was up around 59% to $69 million.Over the long term, Phipps said "we see potential from the company's Parkinson's disease franchise (Vyalev and tavapadon) as meaningful growth drivers and strong potential from the company's late-stage ADC portfolio (ABBV706 and ABBV400)."Meanwhile, AbbVie boosted its full-year profit outlook, now anticipating adjusted earnings of $10.61 to $10.65 per share, up from a range of $10.38 to $10.58 previously. Analysts project earnings of $10.51 per share and $60.7 billion in sales for the year.

ADCFinancial Statement

31 Oct 2025

·www.biospace.com

AbbVie’s Immunology Dyad Dominates Again in Q3

iStock, hapabapa Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone. AbbVie’s two-headed immune blocking behemoth continues to grow, with sales of Skyrizi up 46% and Rinvoq up 34% year-over-year. For the quarter, Skyrizi brought in $4.7 billion, while Rinvoq collected $2.2 billion. The company announced the sales results in a third quarter earnings report Friday morning. The pair of drugs are indicated for a suite of immune-mediated conditions, with Skyrizi treating plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Rinvoq covering rheumatoid arthritis, atopic dermatitis and ankylosing spondylitis. Taken together, the pair of drugs are on track to beat the peak sales of AbbVie’s immune-blocking predecessor blockbuster, Humira , which peaked at $21 billion in total sales for 2022. Sales of Humira, which is now without patent protection, dropped 55% to a scant $993 million for the quarter. Earnings AbbVie Pats Own Back as Skyrizi and Rinvoq Rake in Billions Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year. July 31, 2025 · 2 min read · Dan Samorodnitsky Skyrizi and Rinvoq together are forming something of a “one-two punch,” as CEO Robert Michael described it on the call. Earlier this month, the FDA approved an expanded label for Rinvoq in treating ulcerative colitis and Crohn’s disease that allows its use in patients who are ineligible for a TNF-blocker like Skyrizi, essentially funneling patients that couldn’t take one of the company’s drugs towards another. AbbVie’s pipeline-in-a-product approach is continuing to widen, with Rinvoq also being tested in conditions like alopecia areata, where data from a Phase III trial in July showed 40% of patients receiving Rinvoq attaining 80% scalp coverage. In treating another immune-mediated condition, vitiligo, the company yesterday announced that two Phase III trials testing Rinvoq hit their primary endpoints of 50% reduction of vitiligo coverage on patients’ bodies and 75% reduction on the face. Besides the immune portfolio, questions from analysts on the earnings call centered around M&A activities, with analysts wondering if AbbVie might pursue more external business development. The company shelled out $2.1 billion in June for Capstan and its CAR T business, $2 billion for Ichnos Glenmark’s anti-myeloma antibody in July and Gilgamesh’s lead psychedelic drug for $1.2 billion in August. AbbVie’s leadership suggested that it might be cooling on pursuing acquisitions, at least in the late-stage. “We certainly have the financial wherewithal to pursue late-stage opportunities,” Michael said, “but that’s not really a need, given that our current portfolio provides a clear line of sight to growth into the next decade.” “If you look at the more than 30 deals we’ve executed over the last 18-plus months, there’s been a nice mix between immunology, oncology, neuroscience,” Michael added. Like last quarter , AbbVie’s overall earnings were extremely sunny, with net revenues at $15.8 billion for the quarter, up 9.1% year-over-year. The company’s immunology portfolio made up $7.9 billion of that, with an 11.2% increase for the quarter.

Phase 3Clinical ResultAcquisitionBiosimilarImmunotherapy

100 Deals associated with Risankizumab-RZAA

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Risankizumab-RZAA	L04AC18	DB14762

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Crohn's disease, active moderate	China	AbbVie, Inc.	04 Mar 2025
Crohn's disease, active severe	China	AbbVie, Inc.	04 Mar 2025
Colitis, Ulcerative	Japan	AbbVie, Inc.	26 Sep 2022
Crohn Disease	Australia	AbbVie Pty Ltd.	16 Jul 2019
Ulcerative colitis, active moderate	Australia	AbbVie Pty Ltd.	16 Jul 2019
Ulcerative colitis, active severe	Australia	AbbVie Pty Ltd.	16 Jul 2019
Plaque psoriasis	Canada	AbbVie, Inc.	17 Apr 2019
Arthritis, Psoriatic	Japan	AbbVie, Inc.	26 Mar 2019
Erythrodermic psoriasis	Japan	AbbVie, Inc.	26 Mar 2019
Psoriasis vulgaris	Japan	AbbVie, Inc.	26 Mar 2019
Pustular psoriasis	Japan	AbbVie, Inc.	26 Mar 2019
Pustulosis of Palms and Soles	Japan	AbbVie, Inc.	26 Mar 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	Phase 3	United States	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	Australia	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	Canada	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	France	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	Germany	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	Italy	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	Poland	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	Spain	AbbVie, Inc.	08 Jul 2024
Juvenile Idiopathic Arthritis	Phase 3	United Kingdom	AbbVie, Inc.	08 Jul 2024
Keratoderma, Palmoplantar	Phase 3	United States	AbbVie, Inc.	26 Feb 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03675308 (KEEPSAKE 1, ACR2025)	Phase 3	Arthritis, Psoriatic	964	Risankizumab 150 mg	jhblzuprmz(hclcfuqgxp) = uskrfpanfx fgynweurrk (ivpcwczoos ) View more	Positive	24 Oct 2025
				Placebo	jhblzuprmz(hclcfuqgxp) = yzsrfdguoh fgynweurrk (ivpcwczoos ) View more
ACR2025	Not Applicable	Arthritis, Psoriatic	162	Risankizumab 150 mg	ahgstbzzpl(vecvqshzao) = sncqaimrcs zdkymyhknv (crakcbljqo )	Positive	24 Oct 2025
				Risankizumab 150 mg (csDMARD-IR/bDMARD-naïve)	ahgstbzzpl(vecvqshzao) = jfhhreszul zdkymyhknv (crakcbljqo )
ACR2025	Not Applicable	Arthritis, Psoriatic	94	Risankizumab 150 mg	qveyhuntus(wjrawernox) = fddfdnviss aishgjfxqz (jiaalodwkm ) View more	Positive	24 Oct 2025
				Risankizumab 150 mg (csDMARD-IR)	psjlwsgxwf(xffjbbbjyc) = djbfwacvud njgtqgfonj (wfrxuhiiwn ) View more
NCT05283135 (KNOCKOUT, CTgov)	Phase 2	Plaque psoriasis \| Chronic large plaque psoriasis	20	risankizumab (600 mg Baseline)	ntsvchbpkt(eqbghshcrg) = ewdjsizxtu jdnztrhgzy (futxhozhls, vtjdpctsbk - orhjsphosw) View more	-	24 Oct 2025
				risankizumab (300 mg Baseline)	ntsvchbpkt(eqbghshcrg) = zeauauiawl jdnztrhgzy (futxhozhls, bizzlgytbe - ikpxivfwyy) View more
NCT03105102 \| NCT03105128 (MOTIVATE, ADVANCE, FORTIFY, Pubmed \| Clin Gastroenterol Hepatol)	Phase 3	Perianal fistula due to Crohn's disease anti-interleukin-23 p19 monoclonal antibody	-	Risankizumab 1200 mg IV	damximohdm(wfarfaiimw) = ufibpqznfv yyslbcekvy (uzkdhfymbb ) View more	Positive	01 Oct 2025
				Risankizumab 180 mg SC	damximohdm(wfarfaiimw) = pvycifxpvk yyslbcekvy (uzkdhfymbb ) View more
NCT03671148 \| NCT03675308 (KEEPsAKE 1, Pubmed \| Rheumatol Ther)	Phase 3	Arthritis, Psoriatic	1,038	Risankizumab 150 mg	slsnxosyun(ewlxcwswuu) = jseezauqny ajqnmazokz (gsglkpifhw ) View more	Positive	30 Sep 2025
				Placebo	slsnxosyun(ewlxcwswuu) = yhhmtvndne ajqnmazokz (gsglkpifhw ) View more
NCT03398148 \| NCT03398135 (COMMAND, Pubmed \| Clin Gastroenterol Hepatol)	Phase 3	Colitis, Ulcerative	209	Risankizumab 1200mg IV	aiedykgnnq(jgzsyxwibd) = jhwgvvnhob jsywzmplhp (ifxlweaiev ) View more	Positive	01 Sep 2025
				Risankizumab 180mg SC	aiedykgnnq(jgzsyxwibd) = rydoebbrjz jsywzmplhp (ifxlweaiev ) View more
NCT03047395 (LIMMitless, Pubmed \| Am J Clin Dermatol)	Phase 3	Plaque psoriasis	897	Risankizumab 150 mg	iiqqtybind(quqlpdrugc) = zwjujpuqip ojarsjanno (poionnlqae ) View more	Positive	29 Jul 2025
EULAR2025	Not Applicable	Salivary Gland Adenoma, Pleomorphic	60	Guselkumab	pbpxtpcubw(epgbjywdis) = nshdlnxlnj soqcqptbki (xqlxpfamtq )	Negative	11 Jun 2025
NCT04435600 (OptIMMize-1, CTgov)	Phase 3	Plaque psoriasis \| Chronic large plaque psoriasis	139	Risankizumab (Part 1: Risankizumab)	xrwthfvakc = zwhixbxjmo lowvpvgwku (nrwhxrkcmm, foicaaruwy - fyijnboihg) View more	-	20 May 2025
				Ustekinumab (Part 2 Period A: Ustekinumab)	xrwthfvakc = cgtheevtbm lowvpvgwku (nrwhxrkcmm, nrkmhnwfep - flelfsvvjr) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Risankizumab-RZAA

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation